Transmedics Group, INC Form 4 insider transactions

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold common stock on June 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Stephen Gordon, CFO of TransMedics Group, reported the sale of 20,000 shares of common stock and the exercise of options to acquire 18,000 shares on May 29, 2024.

Director David Weill of TransMedics Group, Inc. sold 1,193 shares of common stock on May 29, 2024, at a price of $141.65 per share.

Director David Weill reported acquiring 732 shares of common stock and options to purchase 1,154 shares of TransMedics Group, Inc. stock.

Director Edward M. Basile reported the acquisition of 732 restricted stock units and 1,154 stock options in TransMedics Group, Inc. on May 23, 2024.

Director Thomas James Gunderson acquired 732 shares of common stock and 1,154 stock options in TransMedics Group, Inc. on May 23, 2024.

Director James R. Tobin reported the acquisition of common stock and stock options in TransMedics Group, Inc.

Director Merilee Raines acquired 732 shares of common stock and stock options for 1,154 shares in TransMedics Group, Inc.

Director Edwin M. Kania Jr. reports acquisition of restricted stock units and stock options in TransMedics Group, Inc.

Director Stephanie Lovell reports acquisition of 732 shares of common stock and 1,154 stock options in TransMedics Group, Inc.

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares of common stock on May 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director David Weill of TransMedics Group, Inc. sold 2,500 shares of common stock at a price of $129.82 on May 10, 2024.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, files an amended Form 4 to correct a clerical error regarding the direct and indirect ownership of common stock.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, files an amended Form 4 to correct a clerical error in a previous filing regarding the nature of ownership of shares sold on May 1, 2024.

Nicholas Corcoran, SVP of Supply Chain and Operations at TransMedics Group, sold 3,222 shares of common stock at an average price of $129.91 on May 6, 2024.

Chief Financial Officer of TransMedics Group, Stephen Gordon, exercised stock options and sold shares on May 6, 2024, according to a recent SEC filing.

Director Edward M. Basile of TransMedics Group, Inc. executed multiple sales of common stock on May 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, sold 5,839 shares of common stock at a weighted average price of $130.07 on May 6, 2024, as part of a pre-arranged trading plan.

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold 30,000 shares of common stock at a weighted average price of $130.07, according to a recent SEC filing.

Director James Tobin sold shares of TransMedics Group, Inc. on May 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director James R. Tobin of TransMedics Group, Inc. sold shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

TransMedics Group's CEO, Waleed Hassanein, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Chief Commercial Officer of TransMedics Group, Tamer Khayal, exercised stock options and sold shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

CEO Waleed Hassanein exercised stock options and sold shares of TransMedics Group, Inc. under a pre-arranged trading plan.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Stephen Gordon, CFO of TransMedics Group, exercised stock options and sold 15,000 shares of common stock on April 1, 2024, according to a recent SEC filing.

Tamer Khayal, Chief Commercial Officer of TransMedics Group, reports the exercise of stock options and subsequent sale of shares to cover tax obligations.

Stephen Gordon, CFO of TransMedics Group, sold 1,903 shares of common stock on March 8, 2024, to cover tax withholding obligations related to vesting restricted stock units.